Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Top Cited Papers
Open Access
- 12 March 2009
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 113 (11) , 2386-2393
- https://doi.org/10.1182/blood-2008-07-162503
Abstract
Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely dependent on clinical expertise and observations more than on evidence derived from clinical trials of high scientific quality. One major obstacle to the implementation of such studies and in producing reliable meta-analyses of existing data is a lack of consensus on standardized critical definitions, outcome criteria, and terminology. Moreover, the demand for comparative clinical trials has dramatically increased since the introduction of new classes of therapeutic agents, such as thrombopoietin receptor agonists, and innovative treatment modalities, such as anti-CD 20 antibodies. To overcome the present heterogeneity, an International Working Group of recognized expert clinicians convened a 2-day structured meeting (the Vicenza Consensus Conference) to define standard terminology and definitions for primary ITP and its different phases and criteria for the grading of severity, and clinically meaningful outcomes and response. These consensus criteria and definitions could be used by investigational clinical trials or cohort studies. Adoption of these recommendations would serve to improve communication among investigators, to enhance comparability among clinical trials, to facilitate meta-analyses and development of therapeutic guidelines, and to provide a standardized framework for regulatory agencies.Keywords
This publication has 68 references indexed in Scilit:
- Current Options for the Treatment of Idiopathic Thrombocytopenic PurpuraSeminars in Hematology, 2007
- Drug-Induced Immune ThrombocytopeniaNew England Journal of Medicine, 2007
- Single dose of anti-D immune globulin at 75μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in childrenThe Journal of Pediatrics, 2006
- Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline ThrombocytopeniaPLoS Medicine, 2006
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Acute immune thrombocytopenic purpura: A comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulinThe Journal of Pediatrics, 1994
- Response of Resistant Idiopathic Thrombocytopenic Purpura to Pulsed High-Dose Dexamethasone TherapyNew England Journal of Medicine, 1994
- A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpuraThe Journal of Pediatrics, 1993
- Incidentally Detected Thrombocytopenia in Healthy Mothers and Their InfantsNew England Journal of Medicine, 1988
- Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5S preparationsThe Journal of Pediatrics, 1986